[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II: Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol; 2009 May;22(5):668-78
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.
  • We investigated the role of this phenomenon in the pathogenesis and progression of adenocarcinoma and squamous cell carcinoma of the lung.
  • Archived tissue from primary tumors (n=325), brain metastases (n=48) and adjacent bronchial epithelial specimens (n=192) were analyzed for immunohistochemical expression by image analysis of E-cadherin, N-cadherin, integrin-alpha v beta 6, vimentin, and matrix metalloproteinase-9.
  • High expression of the epithelial-to-mesenchymal transition phenotype (low E-cadherin and high N-cadherin, integrin-alpha v beta 6, vimentin, and matrix metalloproteinase-9) was found in most lung tumors examined, and the expression pattern varied according to the tumor histologic type.
  • Low E-cadherin membrane and high N-cadherin cytoplasmic expression were significantly more common in squamous cell carcinoma than in adenocarcinoma (P=0.002 and 0.005, respectively).
  • The epithelial-to-mesenchymal transition phenotype is commonly expressed in primary squamous cell carcinoma and adenocarcinoma of the lung; this expression occurs early in the pathogenesis of squamous cell carcinoma.
  • Our findings suggest that epithelial-to-mesenchymal transition is a potential target for lung cancer chemoprevention and therapy.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2349-55 [10873086.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4789-96 [11156236.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):949-54; discussion 954-5 [11269479.001]
  • [Cites] Lung Cancer. 2001 Dec;34 Suppl 2:S145-50 [11720756.001]
  • [Cites] Lung Cancer. 2002 May;36(2):115-24 [11955645.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):179-84 [12218298.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1727-33 [12771988.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Sep;24(3):441-9 [12965318.001]
  • [Cites] Cell Commun Adhes. 2003 Mar-Apr;10(2):105-18 [14681060.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):118-32 [14964308.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):430-9 [14739904.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1589-92 [15196544.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):365-75 [15349812.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1301-7 [15365565.001]
  • [Cites] J Pathol. 1996 Oct;180(2):175-80 [8976877.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):256-60 [15627055.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):28-31 [15662113.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):323-30 [15893000.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7568-72 [16140919.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9455-62 [16230409.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8070-8 [16299238.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98 [16361555.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):944-50 [16424029.001]
  • [Cites] Lung Cancer. 2006 Mar;51(3):313-21 [16423426.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Mar;6(2):89-105 [16529540.001]
  • [Cites] Future Oncol. 2005 Dec;1(6):821-8 [16556062.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5338-45 [16707460.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3856-65 [16940349.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):217-23 [17143501.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11194-206 [17145864.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):3-14 [17311529.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Apr;16(4):451-65 [17371194.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5889-95 [17575158.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jan;38(1):95-104 [17673689.001]
  • [Cites] Oncol Rep. 2008 Feb;19(2):377-83 [18202784.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3650-4 [10910081.001]
  • (PMID = 19270647.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106646-04; United States / NCI NIH HHS / CA / R01 CA106646-04; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / R01 CA106646; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / 1R01CA106646
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Integrins; 0 / Vimentin; 0 / integrin alphavbeta6; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS94296; NLM/ PMC2675657
  •  go-up   go-down


2. Chang YS, Chung JH, Shin DH, Chung KY, Kim YS, Chang J, Kim SK, Kim SK: Retinoic acid receptor-beta expression in stage I non-small cell lung cancer and adjacent normal appearing bronchial epithelium. Yonsei Med J; 2004 Jun 30;45(3):435-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid receptor-beta expression in stage I non-small cell lung cancer and adjacent normal appearing bronchial epithelium.
  • Retinoic acid receptor-beta (RAR-beta) is induced by and mediates the growth-inhibitory and apoptotic effects of retinoic acid (RA), suggesting that loss of RAR-beta expression may be one of the critical events involved in the carcinogenesis/ progression of non-small cell lung cancer (NSCLC) and in the responsiveness to retinoid chemotherapy.
  • However, recent contradictory reports that the expression of RAR-beta is associated with poor clinical outcome, and the fact that treatment of serum-deprived type 2 alveolar cells with RA leads to a stimulation of cell proliferation, require the verification of RAR-beta as a biomarker of chemoprevention or prognosis.
  • The expression status of RAR-beta in cancer cells and adjacent normal appearing bronchial epithelium from 39 patients, diagnosed as stage I NSCLC and undergone a curative lung resection, was analyzed in paraffin-embedded tissue sections by IHC staining.
  • The normal appearing bronchial epithelium of 14 out of 33 (42.4%) specimens expressed RAR-beta, whereas 22 out of the 39 (56.4%) stage I NSCLC specimens expressed RAR-beta.
  • RAR-beta was more frequently expressed in the adenocarcinoma (72.7%) than in the squamous cell carcinoma (31.3%) (p=0.026).
  • Neither the expression status in normal appearing adjacent tissue nor that in the tumor tissue had prognostic implications.
  • The higher expression of RAR-beta in cancer tissue, the focal and uneven distribution in normal appearing adjacent bronchial epithelium, and inconsistency with the corresponding tumor tissue, suggest that the expression status of RAR-beta as a biomarker for chemoprevention/early diagnosis or the prognosis of NSCLC requires further consideration.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptors, Retinoic Acid / metabolism. Respiratory Mucosa / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15227730.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor beta
  •  go-up   go-down


3. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Halldén G: Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res; 2009 Mar 01;15(5):1730-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
  • We show that a novel targeting strategy combining oncolytic adenoviral mutants with the standard cytotoxic treatment, gemcitabine, can markedly improve the anticancer potency.
  • Cell viability, mechanism of cell death, and antitumor efficacy in vivo were determined in the pancreatic carcinoma cells PT45 and Suit2, normal human bronchial epithelial cells, and in PT45 xenografts.
  • The corresponding wild-type virus (Ad5) stimulated drug-induced cell killing to a lesser degree.
  • Gemcitabine blocked replication of all viruses despite the enhanced cell killing activity due to gemcitabine-induced delay in G1/S-cell cycle progression, with repression of cyclin E and cdc25A, which was not abrogated by viral E1A-expression.
  • CONCLUSIONS: Our data suggest that oncolytic mutants lacking the antiapoptotic E1B19K gene can improve efficacy of DNA-damaging drugs such as gemcitabine through convergence on cellular apoptosis pathways.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoviridae / genetics. Adenovirus E1B Proteins / genetics. Apoptosis / drug effects. Deoxycytidine / analogs & derivatives. Gene Deletion. Mutation / genetics. Oncolytic Viruses / physiology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Combined Modality Therapy. Drug Synergism. Flow Cytometry. Genetic Therapy. Genetic Vectors. Humans. Immunoblotting. Mice. Mice, Inbred C57BL. Mice, Nude. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S Phase / drug effects. S Phase / physiology. Virus Replication. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1996 Jun 20;12(12):2549-54 [8700513.001]
  • [Cites] J Virol. 1996 Jul;70(7):4805-10 [8676512.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):713-20 [15332115.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1153-62 [15555548.001]
  • [Cites] Ai Zheng. 2004 Dec;23(12):1666-70 [15601557.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):611-23 [15607965.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5003-8 [15958540.001]
  • [Cites] Gene Ther. 2005 Aug;12(15):1198-205 [15800658.001]
  • [Cites] Cancer Gene Ther. 2005 Sep;12(9):725-36 [15818382.001]
  • [Cites] Gene Ther. 2005 Sep;12(17):1333-46 [15920462.001]
  • [Cites] Oncogene. 2005 Oct 13;24(45):6796-808 [16007153.001]
  • [Cites] J Gastrointest Surg. 2005 Nov;9(8):1068-77; discussion 1077-9 [16269377.001]
  • [Cites] J Virol. 2006 Feb;80(4):2000-12 [16439556.001]
  • [Cites] Hum Gene Ther. 2006 Apr;17(4):379-90 [16610926.001]
  • [Cites] Mol Ther. 2006 Jul;14(1):107-17 [16690359.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Cancer Gene Ther. 2008 Jan;15(1):40-50 [18034197.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(5):875-82 [17726607.001]
  • [Cites] Oncogene. 2008 May 15;27(22):3081-90 [18071311.001]
  • [Cites] Cell Death Differ. 2008 Jun;15(6):997-1008 [18274554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 20;105(20):7293-7 [18490659.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):250-9 [10656456.001]
  • [Cites] Hum Gene Ther. 2000 Feb 10;11(3):379-88 [10697113.001]
  • [Cites] Cell Death Differ. 2000 Feb;7(2):177-88 [10713732.001]
  • [Cites] Nat Med. 2000 Aug;6(8):879-85 [10932224.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1134-9 [11017145.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3394-8 [11309298.001]
  • [Cites] Gene Ther. 2001 Feb;8(4):308-15 [11313805.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):401-8 [11433406.001]
  • [Cites] Hum Gene Ther. 2001 Jul 1;12(10):1323-32 [11440625.001]
  • [Cites] J Virol. 2001 Oct;75(20):9844-56 [11559818.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7464-72 [11606381.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7836-46 [11753666.001]
  • [Cites] J Cell Biol. 2002 Jun 10;157(6):909-14 [12058012.001]
  • [Cites] Cancer Cell. 2002 May;1(4):325-37 [12086848.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):555-61 [12576418.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6229-36 [14559808.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1328-35 [14555956.001]
  • [Cites] Mol Ther. 2004 Jun;9(6):786-803 [15194046.001]
  • [Cites] Cancer Gene Ther. 2004 Sep;11(9):585-93 [15338010.001]
  • [Cites] J Virol. 2004 Nov;78(22):12243-51 [15507611.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):891-8 [8094034.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):11-8 [7481839.001]
  • [Cites] J Virol. 1999 Jul;73(7):5333-44 [10364280.001]
  • (PMID = 19223497.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6251; United Kingdom / Cancer Research UK / / C355/6252; United Kingdom / Cancer Research UK / / C355/A6251; United Kingdom / Cancer Research UK / / C355/A6253
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1B Proteins; 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2873675; NLM/ UKMS28738
  •  go-up   go-down


Advertisement
4. Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS: FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer; 2009 Oct 06;9:355
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.
  • VTE is common in patients with cancer and is increased by surgery, chemotherapy, radiotherapy and disease progression.
  • The FRAGMATIC trial will assess the effect of adding dalteparin (FRAGMIN), a type of LMWH, to standard treatment for patients with lung cancer.
  • METHODS/DESIGN: The study design is a randomised multicentre phase III trial comparing standard treatment and standard treatment plus daily LMWH for 24 weeks in patients with lung cancer.
  • Patients eligible for this study must have histopathological or cytological diagnosis of primary bronchial carcinoma (small cell or non-small cell) within 6 weeks of randomisation, be 18 or older, and must be willing and able to self-administer 5000 IU dalteparin by daily subcutaneous injection or have it administered to themselves or by a carer for 24 weeks.
  • Patients will be randomised to one of the two treatment groups in a 1:1 ratio, standard treatment or standard treatment plus dalteparin.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1970 Oct;120(4):527-30 [4097038.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):683-8 [15375485.001]
  • [Cites] N Engl J Med. 1991 May 30;324(22):1565-74 [2027360.001]
  • [Cites] Adv Exp Med Biol. 1992;313:317-27 [1279951.001]
  • [Cites] Adv Exp Med Biol. 1992;313:329-40 [1442268.001]
  • [Cites] Chest. 1993 Jan;103(1 Suppl):20S-29S [8416770.001]
  • [Cites] Circ Res. 1994 Mar;74(3):525-36 [8118960.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):38-45 [8004580.001]
  • [Cites] Br J Surg. 1995 Apr;82(4):496-501 [7613894.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Thromb Haemost. 1995 Jul;74(1):278-81 [8578472.001]
  • [Cites] Kidney Int. 1996 Feb;49(2):437-48 [8821828.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):50-5 [9071899.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):672-7 [9198237.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):781-4 [9332686.001]
  • [Cites] Thromb Haemost. 1998 Jul;80(1):10-23 [9684778.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):22-36 [9890167.001]
  • [Cites] Baillieres Clin Haematol. 1998 Sep;11(3):675-87 [10331099.001]
  • [Cites] Semin Thromb Hemost. 1999;25(2):167-72 [10357084.001]
  • [Cites] Semin Thromb Hemost. 1999;25(2):173-82 [10357085.001]
  • [Cites] BMJ. 1999 Jun 12;318(7198):1571-2 [10364099.001]
  • [Cites] Cancer J Sci Am. 1999 May-Jun;5(3):132-8 [10367166.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(2):105-10 [10378636.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] N Engl J Med. 2000 Dec 21;343(25):1846-50 [11117976.001]
  • [Cites] Semin Thromb Hemost. 2002 Feb;28(1):45-52 [11885025.001]
  • [Cites] Cardiovasc Drug Rev. 2002 Fall;20(3):199-216 [12397367.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):21S-49S [12527563.001]
  • [Cites] Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21 [12814981.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):146-53 [12853587.001]
  • [Cites] Cancer Treat Rev. 2003 Jun;29 Suppl 2:7-9 [12887943.001]
  • [Cites] Blood Coagul Fibrinolysis. 2003 Jun;14(4):341-6 [12945875.001]
  • [Cites] BMJ. 2003 Sep 13;327(7415):597-8 [12969928.001]
  • [Cites] Br J Psychiatry. 2003 Oct;183:323-31 [14519610.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2110-5 [12920044.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] Chest. 2004 Aug;126(2):601-7 [15302749.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1266-71 [15304029.001]
  • [Cites] Semin Thromb Hemost. 1978 Summer;5(1):1-26 [705351.001]
  • (PMID = 19807917.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Databank-accession-numbers] ISRCTN/ ISRCTN80812769
  • [Grant] United Kingdom / Cancer Research UK / / ; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; S79O08V79F / Dalteparin
  • [Other-IDs] NLM/ PMC2761945
  •  go-up   go-down


5. Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, Kim YS, Park HJ, Seo SY, Mills G, Kim KW, Hong WK, Suh YG, Lee HY: A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila); 2008 Dec;1(7):577-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy.
  • The natural compound deguelin has promising preventive and therapeutic activity against diverse cancers by directly binding to heat shock protein-90 and thus suppressing its function.
  • To develop a derivative(s) of deguelin with reduced potential side effects, we synthesized five deguelin analogues (SH-02, SH-03, SH-09, SH-14, and SH-15) and compared them with the parent compound and each other for structural and biochemical features; solubility; and antiproliferative effects on normal, premalignant, and malignant human bronchial epithelial (HBE) and non-small-cell lung cancer (NSCLC) cell lines.
  • One derivative, SH-14, showed several features of potential superiority for clinical use: the highest apoptotic activity; no detectable influence on Src/signal transducer and activator of transcription signaling, which can promote cancer progression and is closely related to pathogenesis of Parkinson's disease (deguelin, SH-02 and SH-03 strongly activated this signaling); better aqueous solubility; and less cytotoxicity to immortalized HBE cells (versus deguelin) at a dose (1 micromol/L) that induced apoptotic activity in most premalignant and malignant HBE and NSCLC cell lines.
  • These collective results suggest that the novel derivative SH-14 has strong potential for cancer chemoprevention and therapy, with equivalent efficacy and lesser toxicity (versus deguelin).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ROTENONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Sci. 2005 Jun;98(2):130-41 [15937404.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4152-61 [15961763.001]
  • [Cites] Acta Pharmacol Sin. 2005 Oct;26(10):1265-73 [16174445.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1634-5 [16288111.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1695-9 [16288123.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1900-11 [16373705.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):473-81 [16397263.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):949-61 [17565155.001]
  • [Cites] Bioinformatics. 2007 Aug 1;23(15):1986-94 [17599930.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):5-14 [17764071.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1765-73 [17426060.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11630-9 [18089792.001]
  • [Cites] Curr Alzheimer Res. 2004 Nov;1(4):277-93 [15975057.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6145-52 [10626805.001]
  • [Cites] Anal Chem. 2000 Apr 15;72(8):1781-7 [10784141.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 2;280(4):1085-92 [11162638.001]
  • [Cites] J Biol Chem. 2001 Feb 9;276(6):3879-84 [11078745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10930-5 [11535829.001]
  • [Cites] J Mol Graph Model. 2002 Jan;20(4):281-95 [11858637.001]
  • [Cites] FEBS Lett. 2002 Jun 19;521(1-3):190-4 [12096713.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):291-302 [12591985.001]
  • [Cites] J Lipid Res. 2003 Sep;44(9):1622-32 [12777465.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42225-33 [12893833.001]
  • [Cites] Neurochem Res. 2004 Mar;29(3):569-77 [15038604.001]
  • [Cites] Int J Pharm. 2004 May 4;275(1-2):133-9 [15081144.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1119-24 [15313408.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7957-68 [15489913.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1536-48 [15494604.001]
  • [Cites] Virology. 1977 Feb;76(2):675-84 [190771.001]
  • [Cites] J Neurochem. 1990 Mar;54(3):823-7 [2154550.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):346-7 [8090205.001]
  • [Cites] Science. 1995 Jul 7;269(5220):81-3 [7541555.001]
  • [Cites] Nat Med. 1995 Mar;1(3):260-6 [7585044.001]
  • [Cites] Cell. 1997 Apr 18;89(2):239-50 [9108479.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3424-8 [9270008.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3429-35 [9270009.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Oct 20;239(2):493-7 [9344858.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:513-609 [9442882.001]
  • [Cites] Annu Rev Neurosci. 1999;22:123-44 [10202534.001]
  • [Cites] Chem Res Toxicol. 2004 Nov;17(11):1540-8 [15540952.001]
  • [Cites] J Neurochem. 2005 Mar;92(6):1521-30 [15748169.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1885-93 [15774780.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3385-91 [15867239.001]
  • [ErratumIn] Cancer Prev Res (Phila Pa). 2009 Feb;2(2):186. Geo, Seung-Yong [corrected to Seo, Seung-Yong]
  • (PMID = 19139008.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109520-01; United States / NCI NIH HHS / CA / CA109520-01; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA109520-05; United States / NCI NIH HHS / CA / R01 CA109520-04; United States / NCI NIH HHS / CA / R01 CA109520-03; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / CA109520-03; United States / NCI NIH HHS / CA / CA109520-05; United States / NCI NIH HHS / CA / CA109520-02; United States / NCI NIH HHS / CA / R01 CA109520-02; United States / NCI NIH HHS / CA / CA109520-04; United States / NCI NIH HHS / CA / R01 CA109520; United States / NCI NIH HHS / CA / R01 CA 109520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 9,10-dimethoxy-3,3-dimethyl-7,7a,13,13atetrahydro-3H-chromeno(3,4-b)pyrano(2,3-h)chromen-7-ol; 0 / Antineoplastic Agents; 03L9OT429T / Rotenone; K5Z93K66IE / deguelin
  • [Other-IDs] NLM/ NIHMS127987; NLM/ PMC2738643
  •  go-up   go-down


6. Boutemy M, Mispelaere D, Krzisch C, Jounieaux V: [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma]. Rev Mal Respir; 2005 Jun;22(3):413-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
  • [Transliterated title] Evaluation de la chimiothérapie associant vinorelbine-ifosfamide-cisplatine dans le traitement des cancers bronchiques non à petites cellules métastatiques.
  • Non small cell lung cancer (NSCLC) represents 80% of bronchial carcinoma of which 40-50% are mefastatic at the time of diagnosis.
  • At present, although the therapeutic benefits are modest, it is now recognised that combination chemotherapy including platinum salts improves the survival of these patients.
  • METHODS: We analysed retrospectively a cohort of 57 patients suffering from stage IV NSCLC treated with chemotherapy combining cisplatin (80 mg/rn2 on day 1), vinorelbine (25 mg/rn2 on days 1 and 8) and ifosfamide (3000 mg/in 2 on day 1), (NIP), repeated every 21 days.
  • All patients were studied in terms of toxicity and overall survival but only 40 (70%) were able to be evaluated in terms of response to treatment (on account of having received more than three cycles of NIP chemotherapy).
  • Median survival without progression was 4.4 months.
  • For the 40 patients for whom chemotherapy was evaluable, the objective response rate was 20%.
  • CONCLUSION: Treatment of stage IV NSCLC with NIP chemotherapy is effective and improves the survival of these patients independently of other prognostic factors such as age, the presence of cerebral metastases, performance status, histological type, the number of metastatic sites or the serum LOH level.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Bronchogenic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Life Tables. Male. Middle Aged. Retrospective Studies. Smoking / adverse effects. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227927.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


7. Huber RM, Flentje M, Schmidt M, Pöllinger B, Gosse H, Willner J, Ulm K, Bronchial Carcinoma Therapy Group: Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol; 2006 Sep 20;24(27):4397-404
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.
  • PURPOSE: The aim of this study was to examine whether, after preceding induction chemotherapy, simultaneous chemoradiotherapy is superior to radiotherapy alone.
  • PATIENTS AND METHODS: Patients with non-small-cell lung cancer in inoperable stage IIIA or IIIB received induction chemotherapy with two cycles of paclitaxel 200 mg/m2 and carboplatin area under the curve 6 every 3 weeks.
  • Patients without progression at restaging after induction chemotherapy were randomly assigned to radiotherapy (60 Gy) or chemoradiotherapy (paclitaxel 60 mg/m2 weekly).
  • The primary end point was overall survival; secondary end points were time to progression, response, and toxicity.
  • RESULTS: Three hundred three patients entered the study, and 276 completed induction chemotherapy.
  • Median follow-up time of all randomly assigned patients was 13.6 months (interquartile range [IQR], 6.4 to 29.0 months), and median follow-up time of the subgroup of censored patients (n = 52) was 37.4 months (IQR, 5.9 to 57.0 months; maximum, 76.1 months).
  • Median survival times in the radiotherapy group and chemoradiotherapy group were 14.1 months (95% CI, 11.8 to 16.3 months) and 18.7 months (95% CI, 14.1 to 23.3 months; difference not statistically significant, P = .091).
  • Median time to progression significantly favored simultaneous chemoradiotherapy (11.5 months; 95% CI, 8.3 to 14.7 months) versus radiotherapy alone (6.3 months; 95% CI, 5.0 to 7.6 months; P < .001, log-rank test).
  • CONCLUSION: Induction chemotherapy followed by chemoradiotherapy with weekly paclitaxel is feasible.
  • Response, time to progression, and survival favor chemoradiotherapy compared with radiotherapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Area Under Curve. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Bartsch V: [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma]. Onkologie; 2006 Mar;29 Suppl 1:1-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
  • The development of an oral formulation of vinorelbine (Navelbine softgelatine capsules, Pierre Fabre Pharma, Freiburg i.Br., Germany) represents a significant advance in the treatment of patients with cancer.
  • Oral chemotherapy is more convenient for the patients and brings significant time savings.
  • However, if severe neutropenia is encountered during the first cycle, treatment is continued with weekly doses of 60 mg/m(2).
  • A randomized phase II comparison of oral vinorelbine at the recommended dose schedule vs. intravenous vinorelbine at 30 mg/(2) in patients with advanced NSCLC found no significant differences in response rate, progression-free and overall survival between the two treatments.
  • In studies of combination chemotherapy using vinorelbine plus cisplatin or carboplatin in advanced NSCLC, or vinorelbine plus taxanes, capecitabine,epirubicin, or the monoclonal HER2/neu antibody trastuzumab in MBC, intravenous vinorelbine could be completely or partially replaced by oral vinorelbine, resulting in maintained efficacy, good tolerability and improved patient convenience.
  • Metronomic chemotherapy is a new treatment approach designed to maximize the antiangiogenic effect.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Availability. Chemotherapy, Adjuvant. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16534241.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  • [Number-of-references] 83
  •  go-up   go-down


9. Serke M, Allica E, Wolf M, Schönfeld N, Kaiser D, Loddenkemper R: [Non-small-cell bronchial carcinoma with pathological N2 involvement: adjuvant radiotherapy versus adjuvant chemo-radiotherapy]. Kongressbd Dtsch Ges Chir Kongr; 2001;118:606-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-small-cell bronchial carcinoma with pathological N2 involvement: adjuvant radiotherapy versus adjuvant chemo-radiotherapy].
  • [Transliterated title] Nicht-kleinzelliges Bronchialkarzinom mit pathologischem N2-Befall: Adjuvante Radiotherapie versus adjuvante Chemo-Radiotherapie.
  • Fifty-eight patients, 28 of them included in a German multicenter study, were treated either with radiotherapy (5 x 2 Gy/50 Gy) or combined radio-chemotherapy (cisplatin 75 mg/m2 d1 in cases with pneumonectomy etoposide 120 mg/m2 d1-3) and Ifosfamid 1.5 mg/m2 d1-4, 3 cycles) following surgery in pN2-NSCLC.
  • Time to progression (TTP) was 27 to 1172 days, median 244 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11824325.001).
  • [Journal-full-title] Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress
  • [ISO-abbreviation] Kongressbd Dtsch Ges Chir Kongr
  • [Language] GER
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  •  go-up   go-down


10. Rosell R, Moran T, Fernanda Salazar M, Mendez P, De Aguirre I, Ramirez JL, Isla D, Cobo M, Camps C, Lopez-Vivanco G, Alberola V, Taron M: The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S131-16S136
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.
  • This review highlights the numerous molecular biology findings in the field of lung cancer with potential therapeutic impact in both the near and distant future.
  • Abundant pre-clinical and clinical data indicate that BRCA1 mRNA expression is a differential modulator of chemotherapy sensitivity.
  • Low levels predict cisplatin sensitivity and antimicrotubule drug resistance, and the opposite occurs with high levels.
  • For the first time, EGFR mutations have been shown to predict dramatic responses in metastatic lung adenocarcinomas, with a threefold increase in time to progression and survival in patients receiving EGFR tyrosine-kinase inhibitors.
  • Understanding the relevance of these findings can help to change the clinical practice in oncology towards customizing chemotherapy and targeted therapies, leading to improvement both in survival and in cost-effectiveness.
  • [MeSH-major] Carcinoma, Bronchogenic / drug therapy. Carcinoma, Bronchogenic / mortality. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality


11. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG: Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol; 2004 Nov 1;22(21):4341-50
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
  • PURPOSE: Local control rates at conventional radiotherapy doses (60 to 66 Gy) are poor in stage III non-small-cell lung cancer (NSCLC).
  • Dose escalation using three-dimensional thoracic conformal radiation therapy (TCRT) is one strategy to improve local control and perhaps survival.
  • PATIENTS AND METHODS: Stage III NSCLC patients with a good performance status (PS) were treated with induction chemotherapy (carboplatin area under the curve [AUC] 5, irinotecan 100 mg/m(2), and paclitaxel 175 mg/m(2) days 1 and 22) followed by concurrent chemotherapy (carboplatin AUC 2 and paclitaxel 45 mg/m(2) weekly for 7 to 8 weeks) beginning on day 43.
  • Pre- and postchemotherapy computed tomography scans defined the initial clinical target volume (CTV(I)) and boost clinical target volume (CTV(B)), respectively.
  • The CTV(I) received 40 to 50 Gy; the CTV(B) received escalating doses of TCRT from 78 Gy to 82, 86, and 90 Gy.
  • The primary objective was to escalate the TCRT dose from 78 to 90 Gy or to the maximum-tolerated dose.
  • Induction CIP was well tolerated (with filgrastim support) and active (partial response rate, 46.2%; stable disease, 53.8%; and early progression, 0%).
  • The TCRT dose was escalated from 78 to 90 Gy without dose-limiting toxicity.
  • Late toxicity consisted of grade 2 esophageal stricture (n = 3), bronchial stenosis (n = 2), and fatal hemoptysis (n = 2).
  • The overall response rate was 60%, with a median survival time and 1-year survival probability of 24 months and 0.73 (95% CI, 0.55 to 0.89), respectively.
  • CONCLUSION Escalation of the TCRT dose from 78 to 90 Gy in the context of induction and concurrent chemotherapy was accomplished safely in stage III NSCLC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Area Under Curve. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15514375.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Bayle S, Descourt R, Gouva S, Daniel C, Robinet G: [Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma]. Rev Mal Respir; 2004 Feb;21(1):153-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma].
  • [Transliterated title] Efficacité du gefitinib (Iressa) pour le traitement d'un carcinome bronchioloalvéolaire inopérable.
  • INTRODUCTION: Bronchioloalveolar cell carcinoma (BAC) is a rare bronchial tumour.
  • At present the only curative treatment is surgery and inoperable cases are often resistant to radio and chemotherapy.
  • She then received two courses of chemotherapy leading, at best, to stabilisation of the disease.
  • At that time the treatment decision was simple observation.
  • Six months later when there was progression of the bilateral lesions treatment was initiated with gefitinib 250 mg daily.
  • This lead to rapid improvement in the clinical symptoms and the chest x-ray and CT scan showed evidence of a partial response that persisted one year after the beginning of treatment.
  • CONCLUSION: This observation describes the effect of gefitinib in the treatment of inoperable BAC for which there is, at present, no effective therapy.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15260051.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


13. Lequaglie C, Conti B, Brega Massone PP, Giudice G: Unsuspected residual disease at the resection margin after surgery for lung cancer: fate of patients after long-term follow-up. Eur J Cardiothorac Surg; 2003 Feb;23(2):229-32
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This retrospective study evaluates the survival impact of the residual margin disease after bronchial resection for cancer and suggests tactics in cases of microresidual disease.
  • Residual tumour cells were found on the bronchial resection margins of 39 lobectomies, 12 pneumonectomies, 4 segmental resections and one bilobectomy.
  • Histological findings were: squamous cell carcinoma in 38 cases, adenocarcinoma in 15 and large cell carcinoma in three.
  • In all 56 cases, invasive mucosal carcinoma was found exclusively on the bronchial resection margin.
  • Nineteen patients (59.3%) with early stage tumours (I and II) received adjuvant radiation therapy and only three chemotherapy.
  • Forty-one percent of the stage IIIa patients received radiation therapy and 17.6% chemotherapy: 70.6% died of tumour relapse.
  • Forty percent of the stage IIIb patients received radiation therapy and 20% chemotherapy: 60% died of disease progression.
  • CONCLUSIONS: The prognosis of our stage I or II patients with microresidual tumour on the bronchial resection margin (R1) was similar to that of the patients in the same disease stage, whose resection was microscopically radical (R0) and the same was true of the patients in stage III.
  • In patients with residual tumour cells on the bronchial stump we did not observe worsened long-term survivals.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Bronchial Neoplasms / pathology. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Follow-Up Studies. Humans. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science B.V.
  • (PMID = 12559347.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Friedrich RE: Mental neuropathy (numb chin syndrome) leading to diagnosis of metastatic mediastinal cancer. Anticancer Res; 2010 May;30(5):1819-21
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plain radiographs and computerised tomography (CT) scans revealed the mental foramen on the top of the toothless mandible and a symmetrically depicted mandibular canal.
  • Diagnosis was small-cell bronchial carcinoma (extensive disease, stage grouping II B, Marburg classification).
  • Palliative chemotherapy was ineffective and the patient died with evidence of tumour progression.
  • [MeSH-minor] Aged. Antineoplastic Agents / pharmacology. Carcinoma / diagnosis. Carcinoma / pathology. Disease Progression. Foreign-Body Reaction. Humans. Jaw / pathology. Male. Neoplasm Metastasis. Palliative Care. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592385.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E: Cyclin proteolysis as a retinoid cancer prevention mechanism. Ann N Y Acad Sci; 2001 Dec;952:13-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The retinoids, natural and synthetic derivatives of vitamin A, are active in cancer therapy and prevention.
  • Our prior work revealed that all-trans-retinoic acid (RA) prevented tobacco-specific carcinogenic transformation of cultured human bronchial epithelial cells.
  • To confirm that a specific proteolysis pathway was induced by RA-treatment, a degradation assay was established using in vitro translated cyclin D1 and cellular extracts from RA-treated or untreated human bronchial epithelial cells.
  • Findings were extended to the NT2/D1 human embryonal carcinoma differentiation model where a similar pathway was activated by RA-treatment.
  • To determine whether G1 cyclins were involved directly in bronchial preneoplasia, immunohistochemical expression profiles for cyclins D1 and E were examined.
  • Aberrant expression of these cyclins was frequent in bronchial preneoplasia.
  • Emphasis is placed on retinoid effects on cell cycle progression at G1.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11795432.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA075154; United States / NCI NIH HHS / CA / R01 CA062275; United States / NCI NIH HHS / CA / K01-CA 75154; United States / NCI NIH HHS / CA / R0-1-CA62275; United States / NCI NIH HHS / CA / R01-CA87546
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclins; 0 / Multienzyme Complexes; 0 / Receptors, Retinoic Acid; 0 / Retinoids; 0 / Ubiquitin; 5688UTC01R / Tretinoin; EC 3.4.- / Endopeptidases; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 61
  •  go-up   go-down


16. Dietl B, Marienhagen J, Schaefer C, Pohl F, Kölbl O: [Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging]. Strahlenther Onkol; 2007 Mar;183(3):138-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging.
  • PATIENTS AND METHODS: 600 patients (526 men, 76 women, median age 56 years) with ENT tumors (squamous cell carcinoma histology) were studied retrospectively.
  • The following parameters were analyzed in association with distant metastases: tumor localization, T- and N-category, primary treatment, local tumor control, and second neoplasms.
  • RESULTS: 114/600 patients (19%) developed distant metastases, 29/600 (4.9%) at presentation, 50% within 9.3 months after diagnosis of the primary tumor.
  • Distant metastases were most frequent in stage IV (24.2%), carcinoma of the hypopharynx (25.7%), local recurrence (24.3%), and second neoplasm (31.7%) with the following distribution pattern: pulmonary 61/114 (53.5%), pleural 15/114 (13.1%), osseous 45/114 (39.5%), hepatic 14/114 (12.3%), cerebral 8/114 (7%), cutaneous 14/114 (12.3%).
  • 82/600 (13.6%) patients additionally had second neoplasms, 20 corresponding with synchronous or metachronous bronchial tumors.
  • CONCLUSION: With locally advanced ENT tumor stage IVa/b, carcinoma of the hypopharynx, local recurrence or second neoplasms, at least a pretherapeutic CT of the thorax should be performed because every seventh patient (88/600) developed metastases or second primary tumors within the thoracic space during the course of disease.
  • Regarding the side effects and costs of curative therapy, the definition of generally accepted guidelines for the systemic staging of locally advanced ENT tumors should be undertaken.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Otorhinolaryngologic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Bronchogenic / pathology. Carcinoma, Bronchogenic / secondary. Combined Modality Therapy. Disease Progression. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / pathology. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340072.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Ulmar B, Cakir B, Huch K, Puhl W, Richter M: Posterior stabilisation of a malignant cervico-thoracic vertebral bone defect. Acta Orthop Belg; 2005 Jun;71(3):349-52
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Necrosis of the tumour following radiotherapy or chemotherapy may lead to the development of fistulae between the oesophagus and adjacent tissues and organs.
  • We report the expansion of an extra-luminal oesophageal cancer after resection, invading the cervico-thoracic spine, fortunately without neurological deficit, and leading to instability and formation of a malignant fistula linking the tracheo-bronchial tree to the subarachnoidal space.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Cervical Vertebrae. Esophageal Neoplasms / pathology. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Bone Screws. Combined Modality Therapy. Decompression, Surgical / methods. Disease Progression. Fatal Outcome. Humans. Internal Fixators. Laminectomy / methods. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Palliative Care / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035711.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


18. Stranzl H, Gabor S, Mayer R, Prettenhofer U, Wurzinger G, Hackl A: Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries. Strahlenther Onkol; 2002 Aug;178(8):442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
  • The median time between diagnosis of the primary non-bronchogenic tumor and histopathological diagnosis of the endobronchial metastases was 39 months, range 1-99 months.
  • A total dose of 15-20 Gy was delivered in three to four fractions of 5-6 Gy once a week.
  • No palliative chemotherapy was added.
  • Treatment was judged unsuccessful in three (27%) patients.
  • No patient showed up with local progression.
  • The applied treatment is a safe, effective and well tolerated palliative procedure leading to an improved patient quality of life.
  • [MeSH-major] Brachytherapy / methods. Bronchial Neoplasms / radiotherapy. Iridium Radioisotopes / administration & dosage
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Breast Neoplasms. Carcinoma, Renal Cell / radiotherapy. Carcinoma, Renal Cell / secondary. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / secondary. Dose Fractionation. Female. Follow-Up Studies. Humans. Kidney Neoplasms. Male. Middle Aged. Palliative Care. Prostatic Neoplasms. Radiotherapy Dosage. Rectal Neoplasms. Sigmoid Neoplasms. Time Factors. Tongue Neoplasms. Tonsillar Neoplasms. Urinary Bladder Neoplasms. Uterine Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12240550.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


19. Yamashita Y, Mukaida H, Hirabayashi N, Takiyama W: Cerebral air embolism after intrathoracic anti-cancer drug administration. Ann Thorac Surg; 2006 Sep;82(3):1121-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral air embolism after intrathoracic anti-cancer drug administration.
  • A 73-year-old man was admitted for treatment of pleural dissemination that was a recurrence after right lower bilectomy for advanced lung cancer.
  • Thirty minutes after an anti-drug administration through the chest drainage tube, he lost consciousness shortly after coughing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Embolism, Air / etiology. Intracranial Embolism / etiology. Pleura / injuries. Postoperative Complications / etiology
  • [MeSH-minor] Aged. Brain Edema / etiology. Brain Ischemia / etiology. Bronchial Fistula / etiology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cerebral Infarction / etiology. Chest Tubes. Cisplatin / administration & dosage. Coma / etiology. Combined Modality Therapy. Cough. Disease Progression. Fatal Outcome. Fistula / etiology. Hemiplegia / etiology. Humans. Injections / adverse effects. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Male. Picibanil / administration & dosage. Pleural Cavity. Pleural Effusion, Malignant / drug therapy. Pneumonectomy. Pulmonary Veins

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928561.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 39325-01-4 / Picibanil; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Chu XH, Zhang X, Wang S, Lu XK, Wang XQ, Wang KJ: [Clinical analysis of completion pneumonectomy for pulmonary disease]. Zhonghua Wai Ke Za Zhi; 2007 Aug 15;45(16):1132-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung malignancy accounted for 22 of these cases in which the indication included local recurrence in 18, second primary tumors in 2 and primary malignancies that developed after right upper lobectomies for pulmonary tuberculoma and pulmonary cyst respectively in 2 cases.
  • Benign disease was progression or recurrence of bronchiectasis in 2 cases.
  • There were 16 of 20 lung cancer patients receiving postoperative chemotherapy and 3 with positive residues having radiotherapy.
  • RESULTS: For all patients, the previous thoracotomy incision was reopened and maneuvers such as rib resection, intrapericardial blood vessel ligation, division of the bronchus first, local application of glues and hemostatic agents, and bronchial reinforcement were routinely used.
  • Actuarial 1-, 3-, 5-year survival rates from the time of completion pneumonectomy for patients with lung cancer were 77.3%, 50.0% and 29.4%.
  • For patients with local recurrence, first and second primary bronchogenic carcinoma as well as benign pulmonary disease, treatment should be surgical when a less invasive procedure is not available and the patients are in good health.
  • [MeSH-major] Pneumonectomy / methods. Postoperative Complications / therapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lung Diseases / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005620.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Borrás-Blasco J, Rosique-Robles D, Giner-Marco V, Galan-Brotons A, Casterá E, Costa S: Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid. J Clin Pharm Ther; 2007 Dec;32(6):651-4
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report a case of possible delayed-onset osteonecrosis of the jaw after treatment with zoledronic acid.
  • CASE SUMMARY: A 53-year-old white man with no history of allergic drug reactions had been diagnosed as having bronchial epidermoid carcinoma.
  • He received therapy with docetaxel and zoledronate.
  • Because of metastatic progression of the disease, he started treatment with irinotecan and zoledronate.
  • One year after the last cycle of bisphosphonate therapy, the patient had one tooth extracted.
  • Surgical treatment was chosen, with debridement and a mucosal flap, complemented with antibiotic therapy.
  • DISCUSSION: Osteonecrosis of the jaws has recently emerged as a potential complication of bisphosphonate therapy in patients with metastatic cancer undergoing dental surgery.
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021344.001).
  • [ISSN] 0269-4727
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down






Advertisement